ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025
- Divestiture of Pharmaloz manufacturing for $23 million, saving over $2 million annually
- Significant cost reductions through genomics lab closure ($6M/year savings) and reduced headcount
- Management's voluntary salary deferrals demonstrate alignment with shareholder interests
- Potential $50 million recovery through Crown Medical Collections
- Improved gross margin to 36.8% from -2.5% year-over-year
- Stockholders' equity increased to $15.1M from $7.4M in December 2024
- Revenue declined 41.7% to $1.4M from $2.4M year-over-year
- Net loss of $4.7M in Q1 2025
- Low cash position of $88,000, down from $678,000 in December 2024
- Potential Nasdaq listing compliance issues due to stock price
- No revenue generated from diagnostic services
Insights
ProPhase Labs radically restructures operations while pursuing multiple potential liquidity events amid concerning financial position.
ProPhase Labs' Q1 2025 results reveal a company in transition, implementing dramatic cost-cutting measures while pursuing several potential value-unlocking initiatives. The financial picture shows significant challenges with revenue dropping to
The strategic restructuring is substantial - the company has divested Pharmaloz manufacturing for
Three potential value-creation events stand out: 1) The possible sale of Nebula Genomics, with its 16-petabyte genomic dataset spanning 130 countries; 2) A
What's particularly noteworthy is the BE-Smart test's differentiation through mass spectrometry rather than traditional immunohistochemistry or PCR, potentially offering superior sensitivity and specificity. The recent judicial ruling vacating FDA regulation of Laboratory Developed Tests could accelerate its path to market.
The company's working capital has improved to
ProPhase's survival hinges on unproven liquidity events amid severe cash constraints, despite promising diagnostic technology.
The BE-Smart esophageal cancer diagnostic test represents ProPhase's most scientifically promising asset. This test utilizes mass spectrometry technology to analyze tissue samples from routine endoscopies, potentially offering superior accuracy compared to traditional immunohistochemistry or PCR-based approaches. The submission for peer review in the Journal of Clinical Gastroenterology and Hepatology with Dr. Christopher Hartley from Mayo Clinic as senior author lends credibility to the technology.
What's particularly significant is the favorable regulatory environment resulting from the April 1, 2025 court ruling that vacated FDA oversight of Laboratory Developed Tests (LDTs). This dramatically shortens BE-Smart's path to commercialization as an LDT, potentially allowing market entry in 2025 without lengthy FDA review.
The addressable market is substantial - tens of millions of Americans under surveillance for esophageal disease represent a significant commercial opportunity. The test's ability to identify patients at highest risk for progression to esophageal adenocarcinoma addresses a critical clinical need.
However, the company's precarious financial position cannot be overstated. With only
The company's survival appears contingent on at least one of their speculative liquidity events materializing quickly: the Nebula Genomics sale (comparing to 23andMe's
Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months
Completes Significant Reductions in Overhead and Expenses
BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal Hepatology
Company to hold a virtual conference call Tuesday, May 20, 2025, at 10:00 AM ET
GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today reported its financial and operational results for Q1 ended March 31, 2025, and outlined significant strategic corporate developments.
Ted Karkus, CEO of ProPhase Labs, will present to shareholders today, May 20, 2025, at 10:00 a.m. EST during the live Virtual Non-Deal Roadshow Series. The details are available below.
In January 2025, the Company completed the divestiture of its Pharmaloz manufacturing operations for approximately
Q1 2025 therefore marks a transformation in the company’s trajectory with the goal of becoming a lean operating company that develops assets with significant potential but with much lower overhead and less risk to shareholders.
Nasdaq Listing Qualifications
The Company has been in contact with Nasdaq regarding listing qualifications. Nasdaq has indicated that its policy is to only announce extensions for continued listing after the first 6-month notification period expires. However, the Company has confirmed that it is presently in listing compliance other than stock price. Furthermore, in Q1, stockholder’s equity increased significantly (and was already in compliance.) Therefore, given these most recent communications, the Company believes that it will receive the 6-month extension when the first 6-month period expires in late June.
Company Moves Forward With Sale of Nebula Genomics
The Company has engaged ThinkEquity to pursue strategic alternatives for ProPhase’s wholly-owned subsidiary Nebula Genomics. Under new leadership from Jason Karkus, Nebula has been strategically restructured, now allowing for the potential sale at an attractive valuation. The pitch deck and supporting materials have been created and outreach to a significant number of potential acquirers has already been completed. The Company believes that one or more LOIs could be forthcoming in the coming weeks and that a sale could occur within 3-4 months, if not sooner.
The Company believes that Nebula is a compelling acquisition candidate, offering a uniquely diverse 16-petabyte DNA dataset (equivalent to roughly 150 million ancestry SNP-based tests), with samples spanning 130 countries. We believe that Nebula’s dataset is one of the largest and most diverse genomic datasets in the world. Nebula delivers full WGS coverage and proprietary bioinformatics, generating over 350 personalized health, wellness and advanced ancestry reports. Its scalable, subscription-based revenue model, with strong margins on renewals, further enhances its commercial appeal. Recent transactions in the genomics sector, such as the recently announced sale of substantially all of 23andMe’s assets to Regeneron for
Crown Medical Collections estimates the recovery of approximately
The Company believes that Crown Medical’s efforts should start to generate significant cash flow within the next few months and in some cases, possibly sooner. If Crown’s efforts succeed, this could serve as a significant, non-dilutive financial influx in the second half of 2025 to support strategic development of ProPhase’s core businesses. Notably, the Company currently carries only
BE-Smart Submitted for Peer Review to the Journal of Clinical Gastrointestinal Hepatology
A new clinical study evaluating the BE-Smart® molecular analysis platform for patients with Barrett’s esophagus, a precancerous condition that can progress to esophageal adenocarcinoma, has been submitted for peer review to the Journal of Clinical Gastroenterology and Hepatology”. Led by senior author Dr. Christopher Hartley, a GI pathologist at the Mayo Clinic, the study highlights BE-Smart’s ability to accurately stratify disease severity and identify patients most likely to progress to cancer. This submission is an important next step toward the goal of commercialization later this year as a laboratory developed test (LDT).
There are tens of millions of Americans currently under active surveillance for esophageal disease, with an urgent need for tools that improve clinical testing and enable more personalized, timely interventions. BE-Smart delivers best-in-class sensitivity and specificity by leveraging proprietary biomarkers from FFPE tissue obtained from routine endoscopies, allowing for earlier and more precise identification of high-risk patients. Unlike current third-party tests that rely on immunohistochemistry or PCR-based test for legacy oncology biomarkers that can be prone to higher degree of false positives, the BE-Smart test is a more accurate approach using mass spectrometry to quantify the unique disease biology through molecular features directly linked to carcinogenesis.
On April 1, 2025, a federal judge vacated the FDA rule on LDTs, determining that LDTs, like BE-Smart, are not subject to FDA regulatory oversight (source: ASCP News). This landmark ruling is expected to significantly accelerate the commercialization of BE-Smart by streamlining the pathway to market, enabling faster adoption by healthcare providers while maintaining rigorous clinical validation standards. In addition to improving diagnostic precision, this state-of-the-art platform offers patients greater clarity and peace of mind as they navigate ongoing disease management.
The anticipated publication comes at a pivotal moment, as the FDA signals its intention to roll back enforcement of LDT regulations, potentially accelerating access to advanced diagnostics like BE-Smart. Existing molecular tests and pathology workflows frequently fall short in sensitivity, resolution, or tissue efficiency, leaving clinicians with an incomplete picture of disease biology. BE-Smart sets a new benchmark by extracting more clinically relevant information from less tissue, enabling actionable insights that legacy tools cannot provide.
ProPhase Labs owns the full intellectual property portfolio behind BE-Smart. This includes a foundational patent family that enables detection of previously unrecognized molecular hallmarks driving esophageal disease progression. This exclusive capability not only differentiates BE-Smart from traditional biomarker panels but positions ProPhase at the forefront of precision diagnostics in gastroenterology. The test integrates seamlessly into existing workflows, requires just 1–2 biopsy slices, and offers both clinicians and patients actionable insights without additional tissue collection.
CEO Commentary:
“ProPhase is now sharply focused on unlocking value through strategic asset development and disciplined execution,” said Ted Karkus, CEO of ProPhase Labs. “We’ve taken bold steps to streamline operations, reduce overhead and align our resources with opportunities that we believe have real value. With BE-Smart nearing commercialization and a robust pipeline of potential liquidity events, we believe we are well-positioned to create meaningful, long-term shareholder value. We’re optimistic about what’s ahead—the next few months could be a turning point as we move closer to several major milestones.”
CEO to present to Shareholders
ProPhase will also present to shareholders today, May 20, 2025, at 10am EST during the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. During this presentation, Ted Karkus will offer further insights into the Company’s trajectory and respond to investor questions.
REGISTER HERE:
| ● | To ensure smooth connectivity, please access this link using the latest version of Google Chrome. |
Financial Results
Three Months Ended March 31, 2025 as Compared to the Three Months Ended March 31, 2024
For the three months ended March 31, 2025, net revenue was
Cost of revenues for the three months ended March 31, 2025 were
We realized a gross margin profit of
General and administration expenses for the three months ended March 31, 2025 were
Research and development costs for the three months ended March 31, 2025 were
As a result of the effects described above, net loss from the continuing operations for the three months ended March 31, 2025 was
Our aggregate cash and cash equivalents as of March 31, 2025 were
About ProPhase Labs Inc.
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development – such as our potentially life-saving test for the early detection of esophageal cancer – and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com
Forward-Looking Statements
Except for the historical information contained herein, this document contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our expectations regarding the future revenue growth potential of each of our subsidiaries, our expected timeline for commercializing our BE-Smart Esophageal Cancer Test, our expectations regarding future liquidity events, the success of our efforts to collect accounts receivables and anticipated timeline for any payments relating thereto, and our ability to successfully transition into a consumer products company. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.
The information contained in this press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. The statements made herein reflect the Company’s current views with respect to potential business opportunities and are based on currently available information, assumptions, and expectations. These statements are not guarantees of future performance or outcomes and are subject to risks and uncertainties. Comparisons to other companies or transactions, such as the referenced sale of 23andMe to Regeneron, are provided solely for illustrative purposes and do not imply any specific valuation or outcome for Nebula or any potential transaction involving it. No assurance can be given that any transaction will be pursued or consummated.
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman: jboidman@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com
ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| March 31, 2025 | December 31, 2024 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 88 | $ | 678 | ||||
| Accounts receivable, net | 20,204 | 20,058 | ||||||
| Inventory, net | 1,145 | 1,143 | ||||||
| Prepaid expenses and other current assets | 3,333 | 2,615 | ||||||
| Current assets in discontinued operations | — | 6,143 | ||||||
| Total current assets | 24,770 | 30,637 | ||||||
| Property, plant and equipment, net | 6,567 | 7,501 | ||||||
| Prepaid expenses, net of current portion | 135 | 217 | ||||||
| Operating lease right-of-use asset, net | 3,994 | 4,115 | ||||||
| Intangible assets, net | 9,104 | 9,750 | ||||||
| Goodwill | 5,231 | 5,231 | ||||||
| Other assets | 310 | 310 | ||||||
| Non-current assets in discontinued operations | — | 5,439 | ||||||
| TOTAL ASSETS | $ | 50,111 | $ | 63,200 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 13,326 | $ | 13,717 | ||||
| Accrued diagnostic services | 43 | 31 | ||||||
| Accrued advertising and other allowances | 151 | 151 | ||||||
| Finance lease liabilities | 1,956 | 2,147 | ||||||
| Operating lease liabilities | 1,399 | 1,214 | ||||||
| Short-term loan payable, net of discount of | 2,450 | 3,207 | ||||||
| Deferred revenue | 1,600 | 1,698 | ||||||
| Income tax payable | 1,464 | 1,987 | ||||||
| Other current liabilities | 1,663 | 2,115 | ||||||
| Current liabilities in discontinued operations | — | 5,867 | ||||||
| Total current liabilities | 24,052 | 32,134 | ||||||
| Non-current liabilities: | ||||||||
| Unsecured promissory notes, net of discount of | 9,873 | |||||||
| Unsecured long-term debt, net of discount of | 1,834 | 1,779 | ||||||
| Due to sellers | 2,000 | 2,000 | ||||||
| Deferred revenue, net of current portion | 739 | 784 | ||||||
| Operating lease liabilities, net of current portion | 3,695 | 3,762 | ||||||
| Finance lease liabilities, net of current portion | 2,673 | 2,591 | ||||||
| Non-current liabilities in discontinued operations | — | 2,924 | ||||||
| Total non-current liabilities | 10,941 | 23,713 | ||||||
| Total liabilities | 34,993 | 55,847 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| Stockholders’ equity | ||||||||
| Preferred stock authorized 1,000,000, | — | — | ||||||
| Common stock authorized 50,000,000, | 29 | 23 | ||||||
| Additional paid-in capital | 119,837 | 129,921 | ||||||
| Subscription receivable | (480 | ) | — | |||||
| Accumulated deficit | (54,427 | ) | (58,393 | ) | ||||
| Treasury stock, at cost, 8,692,005 and 12,940,967 shares (1), respectively | (49,643 | ) | (64,000 | ) | ||||
| Accumulated other comprehensive loss | (198 | ) | (198 | ) | ||||
| Total stockholders’ equity | 15,118 | 7,353 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 50,111 | $ | 63,200 | ||||
(1) This is net of 6,000,000 collateral shares.
See accompanying notes to these condensed consolidated financial statements
ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except per share amounts)
(unaudited)
| For the three months ended | ||||||||
| March 31, 2025 | March 31, 2024 | |||||||
| Revenues, net | $ | 1,431 | $ | 2,356 | ||||
| Cost of revenues | 905 | 2,416 | ||||||
| Gross profit (loss) | 526 | (60 | ) | |||||
| Operating expenses: | ||||||||
| General and administration | 4,092 | 7,299 | ||||||
| Research and development | 97 | 272 | ||||||
| Total operating expenses | 4,189 | 7,571 | ||||||
| Loss from operations | (3,663 | ) | (7,631 | ) | ||||
| Debt extinguishment loss | (431 | ) | — | |||||
| Interest expense | (539 | ) | (441 | ) | ||||
| Other expense | (45 | ) | (18 | ) | ||||
| Loss from operations before income taxes | (4,678 | ) | (8,090 | ) | ||||
| Income tax (expense) benefit | — | 2,566 | ||||||
| Loss from continuing operations after income taxes | (4,678 | ) | (5,524 | ) | ||||
| Discontinued operations: | ||||||||
| Loss from discontinued operations, net of tax | (102 | ) | (741 | ) | ||||
| Gain from disposal of discontinued operations | 8,746 | — | ||||||
| Income (loss) from discontinued operations | 8,644 | (741 | ) | |||||
| Net income (loss) | $ | 3,966 | $ | (6,265 | ) | |||
| Other comprehensive income: | ||||||||
| Unrealized gain on marketable securities | — | 160 | ||||||
| Total comprehensive loss | $ | 3,966 | $ | (6,105 | ) | |||
| Net earnings (loss) per share: | ||||||||
| Loss from continuing operations, basic and diluted | $ | (0.13 | ) | $ | (0.32 | ) | ||
| Income (loss) from discontinued operations, basic and diluted | $ | 0.25 | $ | (0.04 | ) | |||
| Net earnings (loss) per share, basic and diluted | $ | 0.11 | $ | (0.36 | ) | |||
| Weighted average common shares outstanding: | ||||||||
| Basic | 35,233 | 17,207 | ||||||
| Diluted | 35,233 | 17,207 | ||||||
See accompanying notes to these condensed consolidated financial statements
ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
| For the three months ended | ||||||||
| March 31, 2025 | March 31, 2024 | |||||||
| Cash flows from operating activities | ||||||||
| Net income (loss) | $ | 3,966 | $ | (6,265 | ) | |||
| Less: Gain (loss) from discontinued operations, net of tax | 8,644 | (741 | ) | |||||
| Net loss from continuing operations | (4,678 | ) | (5,524 | ) | ||||
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||||||||
| Realized loss on marketable debt securities | — | 18 | ||||||
| Depreciation and amortization | 1,482 | 1,605 | ||||||
| Amortization of debt discount | 372 | 140 | ||||||
| Amortization on operating lease right-of-use assets | 121 | 110 | ||||||
| Stock-based compensation expense | 521 | 1,589 | ||||||
| Inventory reserve | — | (63 | ) | |||||
| Loss from disposal of fixed assets | 45 | — | ||||||
| Debt extinguishment loss | 431 | — | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (146 | ) | 1,139 | |||||
| Inventory | (2 | ) | 215 | |||||
| Prepaid expenses and other current assets | (636 | ) | (700 | ) | ||||
| Deferred tax asset | — | (2,612 | ) | |||||
| Other assets | — | 847 | ||||||
| Accounts payable and accrued expenses | (391 | ) | 2,542 | |||||
| Accrued diagnostic services | 12 | (46 | ) | |||||
| Accrued advertising and other allowances | — | (16 | ) | |||||
| Deferred revenue | (143 | ) | (752 | ) | ||||
| Deferred tax liability | — | — | ||||||
| Lease liabilities | 9 | (459 | ) | |||||
| Income tax payable | (523 | ) | (273 | ) | ||||
| Other liabilities | (452 | ) | (639 | ) | ||||
| Net cash used in operating activities - continuing operations | (3,978 | ) | (2,879 | ) | ||||
| Net cash provided by (used in) operating activities - discontinued operations | 597 | (2,261 | ) | |||||
| Net cash used in operating activities | (3,381 | ) | (5,140 | ) | ||||
| Cash flows from investing activities | ||||||||
| Proceeds from sales of marketable securities | — | 3,374 | ||||||
| Proceeds from sales of fixed assets | 53 | — | ||||||
| Capital expenditures | — | (867 | ) | |||||
| Net cash provided by investing activities - continuing operations | 53 | 2,507 | ||||||
| Net cash provided by (used in) investing activities - discontinued operations | 800 | (72 | ) | |||||
| Net cash provided by investing activities | 853 | 2,435 | ||||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of note payable, net | 204 | 2,460 | ||||||
| Proceeds from issuance of common shares, net | 3,278 | — | ||||||
| Repayment of note payable | (1,509 | ) | (185 | ) | ||||
| Net cash provided by financing activities - continuing operations | 1,973 | 2,275 | ||||||
| Net cash used in financing activities - discontinued operations | (35 | ) | (4 | ) | ||||
| Net cash provided by financing activities | 1,938 | 2,271 | ||||||
| Decrease in cash and cash equivalents | (590 | ) | (434 | ) | ||||
| Cash and cash equivalents at the beginning of the period | 678 | 1,609 | ||||||
| Cash and cash equivalents at the end of the period | $ | 88 | $ | 1,175 | ||||
| Supplemental disclosures: | ||||||||
| Cash paid for income taxes | $ | 256 | $ | 318 | ||||
| Interest payments | $ | 376 | $ | 642 | ||||
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Issuance of common stock as commitment fee for future financing | $ | 158 | $ | — | ||||
See accompanying notes to these condensed consolidated financial statements
Non-GAAP Financial Measures and Reconciliation
In an effort to provide investors with additional information regarding our results of operations as determined by accounting principles generally accepted in the United States of America (“GAAP”), we disclose certain non-GAAP financial measures. The primary non-GAAP financial measures we disclose are EBITDA and Adjusted EBITDA.
We define “EBITDA” as net income (loss) before net interest expense, income taxes, depreciation and amortization. Adjusted EBITDA further adjusts EBITDA by excluding acquisition costs, other non-cash items, and other unusual or non-recurring charges (as described in the table below).
Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. These non-GAAP financial measures do not reflect a comprehensive system of accounting, differ from GAAP measures with the same names and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. We compute non-GAAP financial measures using the same consistent method from quarter to quarter and year to year. We may consider whether other significant items that arise in the future should be excluded from the non-GAAP financial measures.
We use EBITDA and Adjusted EBITDA internally to evaluate and manage the Company’s operations because we believe they provide useful supplemental information regarding the Company’s ongoing economic performance. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our operating results primarily because they exclude amounts that are not considered part of ongoing operating results when planning and forecasting and when assessing the performance of the organization. In addition, we believe that non-GAAP financial information is used by analysts and others in the investment community to analyze our historical results and in providing estimates of future performance and that failure to report these non-GAAP measures could result in confusion among analysts and others and create a misplaced perception that our results have underperformed or exceeded expectations.
The following table sets forth the reconciliations of EBITDA and Adjusted EBITDA excluding other costs to the most comparable GAAP financial measures (in thousands):
| For the three months ended | ||||||||
| March 31, 2025 | March 31, 2024 | |||||||
| GAAP loss from continuing operations (1) | $ | (4,678 | ) | $ | (5,524 | ) | ||
| Interest, net | 539 | 441 | ||||||
| Income tax benefit | — | (2,566 | ) | |||||
| Depreciation and amortization | 1,482 | 1,605 | ||||||
| EBITDA | (2,657 | ) | (6,044 | ) | ||||
| Share-based compensation expense | 521 | 1,589 | ||||||
| Non-cash rent expense (2) | 522 | 169 | ||||||
| Adjusted EBITDA from continuing operations | $ | (1,614 | ) | $ | (4,286 | ) | ||
| (1) | We believe that net loss from continuing operations is the financial measure calculated and presented in accordance with GAAP that is most directly comparable to EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA measure the Company’s operating performance without regard to certain expenses. EBITDA and Adjusted EBITDA are not presentations made in accordance with GAAP and the Company’s computation of EBITDA and Adjusted EBITDA may vary from others in the industry. EBITDA and Adjusted EBITDA have important limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of the Company’s results as reported under GAAP. |
| (2) | The non-cash portion of rent, which reflects the extent to which our GAAP rent expense recognized exceeds (or is less than) our cash rent payments. For newer leases, our rent expense recognized typically exceeds our cash rent payments, while for more mature leases, rent expense recognized is typically less than our cash rent payments. |
FAQ
What were ProPhase Labs (PRPH) key financial results for Q1 2025?
How much did ProPhase Labs (PRPH) reduce costs through restructuring in 2025?
What is the potential value of ProPhase Labs (PRPH) Crown Medical Collections initiative?
What is the status of ProPhase Labs (PRPH) BE-Smart esophageal cancer test?
What are the details of ProPhase Labs (PRPH) Nebula Genomics potential sale?
